메뉴 건너뛰기




Volumn 133, Issue 6, 2013, Pages 1479-1488

Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters

Author keywords

conditionally replicative adenovirus; gene therapy; immunosuppression; oncolytic virus; pancreas cancer

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; URACIL PHOSPHORIBOSYLTRANSFERASE; VIRUS DNA;

EID: 84879965657     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28132     Document Type: Article
Times cited : (23)

References (50)
  • 2
    • 76349110981 scopus 로고    scopus 로고
    • Current issues and future directions of oncolytic adenoviruses
    • Yamamoto M, Curiel DT,. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18: 243-50.
    • (2010) Mol Ther , vol.18 , pp. 243-250
    • Yamamoto, M.1    Curiel, D.T.2
  • 3
    • 33846650370 scopus 로고    scopus 로고
    • Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress
    • Liu TC, Galanis E, Kirn D,. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-17.
    • (2007) Nat Clin Pract Oncol , vol.4 , pp. 101-117
    • Liu, T.C.1    Galanis, E.2    Kirn, D.3
  • 4
    • 28844444483 scopus 로고    scopus 로고
    • Recent progress in the battle between oncolytic viruses and tumors
    • Parato KA, Senger D, Forsyth PAJ, et al. Recent progress in the battle between oncolytic viruses and tumors. Nat Rev Cancer 2005; 5: 965-76.
    • (2005) Nat Rev Cancer , vol.5 , pp. 965-976
    • Parato, K.A.1    Senger, D.2    Forsyth, P.A.J.3
  • 5
    • 76349112703 scopus 로고    scopus 로고
    • Intelligent design: Combination therapy with oncolytic viruses
    • Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-63.
    • (2010) Mol Ther , vol.18 , pp. 251-263
    • Ottolino-Perry, K.1    Diallo, J.S.2    Lichty, B.D.3
  • 6
    • 0032503659 scopus 로고    scopus 로고
    • A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
    • Freytag SO, Rogulski KR, Paielli DL, et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-33.
    • (1998) Hum Gene Ther , vol.9 , pp. 1323-1333
    • Freytag, S.O.1    Rogulski, K.R.2    Paielli, D.L.3
  • 7
    • 0033643594 scopus 로고    scopus 로고
    • Therapy of head and neck squamous cell carcinima with an oncolytic adenovirus expressing HSV-tk
    • Morris JC, Wildner O,. Therapy of head and neck squamous cell carcinima with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
    • (2000) Mol Ther , vol.1 , pp. 56-62
    • Morris, J.C.1    Wildner, O.2
  • 8
    • 0035893397 scopus 로고    scopus 로고
    • Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase
    • Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-50.
    • (2001) Cancer Res , vol.61 , pp. 8743-8750
    • Nanda, D.1    Vogels, R.2    Havenga, M.3
  • 9
    • 19944431439 scopus 로고    scopus 로고
    • Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: Significance of timing of 5-fluorouracil administration
    • Seo E, Abei M, Wakayama M, et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res 2005; 65: 546-52.
    • (2005) Cancer Res , vol.65 , pp. 546-552
    • Seo, E.1    Abei, M.2    Wakayama, M.3
  • 10
    • 0036837479 scopus 로고    scopus 로고
    • Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors
    • Oonuma M, Sunamura M, Motoi F, et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer 2002; 102: 51-9.
    • (2002) Int J Cancer , vol.102 , pp. 51-59
    • Oonuma, M.1    Sunamura, M.2    Motoi, F.3
  • 11
    • 63949083337 scopus 로고    scopus 로고
    • Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters
    • Bortolanza S, Bunuales M, Otano I, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17: 614-22.
    • (2009) Mol Ther , vol.17 , pp. 614-622
    • Bortolanza, S.1    Bunuales, M.2    Otano, I.3
  • 12
    • 77953160443 scopus 로고    scopus 로고
    • Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients
    • Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-309.
    • (2010) Cancer Res , vol.70 , pp. 4297-4309
    • Cerullo, V.1    Pesonen, S.2    Diaconu, I.3
  • 13
    • 57749201655 scopus 로고    scopus 로고
    • Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer
    • Kirn DH, Thorne SH,. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
    • (2009) Nat Rev Cancer , vol.9 , pp. 64-71
    • Kirn, D.H.1    Thorne, S.H.2
  • 14
    • 0036830143 scopus 로고    scopus 로고
    • Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency
    • van Beusechem VW, van den Doel PB, Grill J, et al. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002; 62: 6165-71.
    • (2002) Cancer Res , vol.62 , pp. 6165-6171
    • Van Beusechem, V.W.1    Van Den Doel, P.B.2    Grill, J.3
  • 15
    • 0041589480 scopus 로고    scopus 로고
    • E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer
    • Fukuda K, Abei M, Ugai H, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res 2003; 63: 4434-40.
    • (2003) Cancer Res , vol.63 , pp. 4434-4440
    • Fukuda, K.1    Abei, M.2    Ugai, H.3
  • 16
    • 34249812369 scopus 로고    scopus 로고
    • E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers
    • Wakayama M, Abei M, Kawashima R, et al. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin Cancer Res 2007; 13: 3043-50.
    • (2007) Clin Cancer Res , vol.13 , pp. 3043-3050
    • Wakayama, M.1    Abei, M.2    Kawashima, R.3
  • 17
    • 58349108062 scopus 로고    scopus 로고
    • E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer
    • Fukuda K, Abei M, Ugai H, et al. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther 2009; 16: 126-36.
    • (2009) Cancer Gene Ther , vol.16 , pp. 126-136
    • Fukuda, K.1    Abei, M.2    Ugai, H.3
  • 18
    • 0024164649 scopus 로고
    • Fluorouracil: Biochemistry and pharmacology
    • Pinedo HM, Peters GFJ,. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
    • (1988) J Clin Oncol , vol.6 , pp. 1653-1664
    • Pinedo, H.M.1    Peters, G.F.J.2
  • 19
    • 32944474223 scopus 로고    scopus 로고
    • Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors
    • Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-6.
    • (2006) Cancer Res , vol.66 , pp. 1270-1276
    • Thomas, M.A.1    Spencer, J.F.2    La Regina, M.C.3
  • 20
    • 34548473135 scopus 로고    scopus 로고
    • Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters
    • Bortolanza S, Alzuguren P, Bunuales M, et al. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007; 18: 681-90.
    • (2007) Hum Gene Ther , vol.18 , pp. 681-690
    • Bortolanza, S.1    Alzuguren, P.2    Bunuales, M.3
  • 21
    • 70450200778 scopus 로고    scopus 로고
    • The case of oncolytic viruses versus the immune system: Waiting on the judgement of Solomon
    • Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: Waiting on the judgement of Solomon. Hum Gene Ther 2009; 20: 1119-32.
    • (2009) Hum Gene Ther , vol.20 , pp. 1119-1132
    • Prestwich, R.J.1    Errington, F.2    Diaz, R.M.3
  • 22
    • 79960292554 scopus 로고    scopus 로고
    • Immune recruitment and therapeutic synergy: Keys to optimizing oncolytic viral therapy?
    • Naik JD, Twelves CJ, Selby PJ, et al. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res 2011; 17: 4214-24.
    • (2011) Clin Cancer Res , vol.17 , pp. 4214-4224
    • Naik, J.D.1    Twelves, C.J.2    Selby, P.J.3
  • 23
    • 85027956453 scopus 로고    scopus 로고
    • Thunder and lightning: Immunotherapy and oncolytic viruses collide
    • Melcher A, Parato K, Rooney CM, et al. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19: 1008-16.
    • (2011) Mol Ther , vol.19 , pp. 1008-1016
    • Melcher, A.1    Parato, K.2    Rooney, C.M.3
  • 24
    • 0034691508 scopus 로고    scopus 로고
    • Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
    • Chen Y, Yu DC, Charlton D, et al. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-67.
    • (2000) Hum Gene Ther , vol.11 , pp. 1553-1567
    • Chen, Y.1    Yu, D.C.2    Charlton, D.3
  • 25
    • 8444244419 scopus 로고    scopus 로고
    • Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model
    • Tsai V, Johnson DE, Rahman A, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004; 10: 7199-206.
    • (2004) Clin Cancer Res , vol.10 , pp. 7199-7206
    • Tsai, V.1    Johnson, D.E.2    Rahman, A.3
  • 26
    • 60049098649 scopus 로고    scopus 로고
    • Effect of pre-existing immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters
    • Dhar D, Spencer JF, Toth K, et al. Effect of pre-existing immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130-9.
    • (2009) J Virol , vol.83 , pp. 2130-2139
    • Dhar, D.1    Spencer, J.F.2    Toth, K.3
  • 27
    • 70349873326 scopus 로고    scopus 로고
    • Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model
    • Dhar D, Spencer JF, Toth K, et al. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009; 17: 1724-32.
    • (2009) Mol Ther , vol.17 , pp. 1724-1732
    • Dhar, D.1    Spencer, J.F.2    Toth, K.3
  • 28
    • 0031710507 scopus 로고    scopus 로고
    • Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
    • Bass KK, Mastrangelo MJ,. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998; 47: 1-12.
    • (1998) Cancer Immunol Immunother , vol.47 , pp. 1-12
    • Bass, K.K.1    Mastrangelo, M.J.2
  • 29
    • 33847368549 scopus 로고    scopus 로고
    • + regulatory T cells and restores T and NK effector functions in end stage cancer patients
    • + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-8.
    • (2007) Cancer Immunol Immunother , vol.56 , pp. 641-648
    • Ghiringhelli, F.1    Menard, C.2    Puig, P.E.3
  • 30
    • 80052420081 scopus 로고    scopus 로고
    • Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
    • Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19: 1737-46.
    • (2011) Mol Ther , vol.19 , pp. 1737-1746
    • Cerullo, V.1    Diaconu, I.2    Kangasniemi, L.3
  • 31
    • 0032814773 scopus 로고    scopus 로고
    • Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
    • Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-7.
    • (1999) Nat Med , vol.5 , pp. 881-887
    • Ikeda, K.1    Ichikawa, T.2    Wakimoto, H.3
  • 32
    • 33748088164 scopus 로고    scopus 로고
    • Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
    • Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Accad Sci USA 2006; 103: 12873-8.
    • (2006) Proc Natl Accad Sci USA , vol.103 , pp. 12873-12878
    • Fulci, G.1    Breymann, L.2    Gianni, D.3
  • 33
    • 54749109597 scopus 로고    scopus 로고
    • Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model
    • Thomas MA, Spencer JF, Toth K, et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-73.
    • (2008) Mol Ther , vol.16 , pp. 1665-1673
    • Thomas, M.A.1    Spencer, J.F.2    Toth, K.3
  • 34
    • 40749090005 scopus 로고    scopus 로고
    • Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
    • Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14: 259-69.
    • (2008) Clin Cancer Res , vol.14 , pp. 259-269
    • Qiao, J.1    Wang, H.2    Kottke, T.3
  • 35
    • 35549009347 scopus 로고    scopus 로고
    • An immunocompetent murine model for oncolysis with an armed and targeted measles virus
    • Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15: 1991-7.
    • (2007) Mol Ther , vol.15 , pp. 1991-1997
    • Ungerechts, G.1    Springfeld, C.2    Frenzke, M.E.3
  • 36
    • 65249177789 scopus 로고    scopus 로고
    • Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide
    • Lun XQ, Jang J-H, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009; 15: 2777-88.
    • (2009) Clin Cancer Res , vol.15 , pp. 2777-2788
    • Lun, X.Q.1    Jang, J.-H.2    Tang, N.3
  • 37
    • 80051580618 scopus 로고    scopus 로고
    • Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths
    • Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
    • (2011) CA Cancer J Clin , vol.61 , pp. 212-236
    • Siegel, R.1    Ward, E.2    Brawley, O.3
  • 38
    • 0032985541 scopus 로고    scopus 로고
    • Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database
    • Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
    • (1999) J Am Coll Surg , vol.189 , pp. 1-7
    • Sener, S.F.1    Fremgen, A.2    Menck, H.R.3
  • 39
    • 0037279047 scopus 로고    scopus 로고
    • Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer
    • Dehari H, Ito Y, Nakamura T, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther 2003; 10: 75-85.
    • (2003) Cancer Gene Ther , vol.10 , pp. 75-85
    • Dehari, H.1    Ito, Y.2    Nakamura, T.3
  • 40
    • 79959708509 scopus 로고    scopus 로고
    • EpCAM- and EGFR- targeted selective gene therapy for biliary cancers using Z33-fiber modified adenovirus
    • Kawashima R, Abei M, Fukuda K, et al. EpCAM- and EGFR- targeted selective gene therapy for biliary cancers using Z33-fiber modified adenovirus. Int J Cancer 2011; 129: 1244-53.
    • (2011) Int J Cancer , vol.129 , pp. 1244-1253
    • Kawashima, R.1    Abei, M.2    Fukuda, K.3
  • 41
    • 21044457510 scopus 로고    scopus 로고
    • Enhanced oncolysis by a tropism-modified telomerase-specific replication selective adenoviral agent OBP-405 ('Telomelysin-RGD')
    • Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005; 24: 3130-40.
    • (2005) Oncogene , vol.24 , pp. 3130-3140
    • Taki, M.1    Kagawa, S.2    Nishizaki, M.3
  • 42
    • 84874771300 scopus 로고    scopus 로고
    • Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses
    • Peng K-W, Myers R, Greenslade A, et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 2013; 20: 255-61
    • (2013) Gene Ther , vol.20 , pp. 255-261
    • Peng, K.-W.1    Myers, R.2    Greenslade, A.3
  • 44
    • 33646907924 scopus 로고    scopus 로고
    • Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus
    • Zhi Y, Figueredo J, Kobinger GP, et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 2006; 17: 500-6.
    • (2006) Hum Gene Ther , vol.17 , pp. 500-506
    • Zhi, Y.1    Figueredo, J.2    Kobinger, G.P.3
  • 45
    • 0029743163 scopus 로고    scopus 로고
    • Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenovirus vectors to mouse liver and lung
    • Jooss K, Yang Y, Wilson JM,. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenovirus vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-66.
    • (1996) Hum Gene Ther , vol.7 , pp. 1555-1566
    • Jooss, K.1    Yang, Y.2    Wilson, J.M.3
  • 46
    • 0029934048 scopus 로고    scopus 로고
    • Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector
    • Smith TA, White BD, Gardner JM, et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996; 3: 496-502.
    • (1996) Gene Ther , vol.3 , pp. 496-502
    • Smith, T.A.1    White, B.D.2    Gardner, J.M.3
  • 47
    • 33751005823 scopus 로고    scopus 로고
    • Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging
    • Lamfers M, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006; 14: 779-88.
    • (2006) Mol Ther , vol.14 , pp. 779-788
    • Lamfers, M.1    Fulci, G.2    Gianni, D.3
  • 48
    • 79960298256 scopus 로고    scopus 로고
    • International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
    • Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011; 29: 5203-9.
    • (2011) Vaccine , vol.29 , pp. 5203-5209
    • Barouch, D.H.1    Kik, S.V.2    Weverling, G.J.3
  • 49
    • 80052406557 scopus 로고    scopus 로고
    • Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
    • Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
    • (2011) Nature , vol.477 , pp. 99-102
    • Breitbach, C.J.1    Burke, J.2    Jonker, D.3
  • 50
    • 79953828406 scopus 로고    scopus 로고
    • Potential targets for pancreatic cancer immunotherapeutics
    • Dodson LF, Hawkins WG, Goedegebuure P,. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011; 3: 517-37. Technology Technology
    • (2011) Immunotherapy , vol.3 , pp. 517-537
    • Dodson, L.F.1    Hawkins, W.G.2    Goedegebuure, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.